Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | CA7 | P43166 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18659987 | 0.84 | CA1 (0.60) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL18661107 | 0.84 | GAA (0.53) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL16297725 | 0.83 | HTT (0.57) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL22984085 | 0.83 | FOLH1 (0.59) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL14390133 | 0.80 | POLB (0.58) | HTTKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL3844592 | 0.79 | HTT (0.79) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL30305908 | 0.78 | ALDH1A1 (0.49) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL18660023 | 0.78 | LMNA (0.51) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL18461223 | 0.78 | CA1 (0.50) | GAAHTTUSP2CA1CA2 | |
| SCHEMBL22488350 | 0.78 | FOLH1 (0.46) | GAAHTTUSP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045564-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2021-06-29 | — | — | US | disclosed |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-09-03 | — | — | US | disclosed |
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2013-05-30 | — | — | US | disclosed |
| US-8444954-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| US-8420050-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| US-20120009122-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2012-01-12 | — | — | US | disclosed |
| US-20110250133-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2011-10-13 | — | — | US | disclosed |
| US-7922998-B2 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2011-04-12 | — | — | US | disclosed |
| US-20110052491-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2011-03-03 | — | — | US | disclosed |
| US-7850947-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2010-12-14 | — | — | US | disclosed |
| US-7611692-B2 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2009-11-03 | — | — | US | disclosed |
| US-20090175786-A1 | Gastrin Releasing Peptide Compounds | BRACCO IMAGING S.P.A. (IT) | 2009-07-09 | — | — | US | disclosed |
| US-20080008649-A1 | Gastrin Releasing Peptide Compounds | BRACCO IMAGING S.P.A. (IT) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | GAA 396/4885HTT 1867/4885USP2 4018/4885 |
| US-20090175786-A1 | Gastrin Releasing Peptide Compounds | GRPR, SSTR5, GIPR | GAA 1821/4885HTT 4761/4885USP2 4345/4885 |
| US-20080008649-A1 | Gastrin Releasing Peptide Compounds | GRPR, SSTR5, GIPR | GAA 1821/4885HTT 4761/4885USP2 4345/4885 |
| US-20120009122-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, CCKBR | GAA 1172/4885HTT 4232/4885USP2 4130/4885 |
| US-20110250133-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | GAA 396/4885HTT 1867/4885USP2 4018/4885 |
| US-11045564-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | GAA 42/4885HTT 4733/4885USP2 3559/4885 |
| US-20110052491-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, CCKBR | GAA 490/4885HTT 3062/4885USP2 3873/4885 |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | GAA 50/4885HTT 4652/4885USP2 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.